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The target epitopes, serotype specificity, and cytolytic function of dengue virus-specific T cells may influence
their theoretical roles in protection against secondary infection as well as the immunopathogenesis of dengue
hemorrhagic fever. To study these factors in an experimental system, we isolated dengue virus-specific CD41
and CD81 T-cell clones from dengue-2 virus-immunized BALB/c mice. The T-cell response to dengue virus in
this mouse strain was heterogeneous; we identified at least five different CD41 phenotypes and six different
CD81 phenotypes. Individual T-cell clones recognized epitopes on the dengue virus pre-M, E, NS1/NS2A, and
NS3 proteins and were restricted by the I-Ad, I-Ed, Ld, and Kd antigens. Both serotype-specific and serotype-
cross-reactive clones were isolated in the CD41 and CD81 subsets; among CD81 clones, those that recognized
the dengue virus structural proteins were serotype specific whereas those that recognized the nonstructural
proteins were serotype cross-reactive. All of the CD81 and one of five CD41 clones lysed dengue virus-infected
target cells. Using synthetic peptides, we identified an Ld-restricted epitope on the E protein (residues 331 to
339, SPCKIPFEI) and a Kd-restricted epitope on the NS3 protein (residues 296 to 310, ARGYISTRVEM
GEAA). These data parallel previous findings of studies using human dengue virus-specific T-cell clones. This
experimental mouse system may be useful for studying the role of the virus serotype and HLA haplotype on
T-cell responses after primary dengue virus infection.
Dengue hemorrhagic fever/dengue shock syndrome (DHF/
DSS), the severe manifestation of infection by the flavivirus
dengue virus, is a significant cause of morbidity and mortality
in tropical regions of the world (20, 36). Recently DHF/DSS
has occurred in increasing numbers and over a wider geo-
graphic distribution. Preexisting immunity to one of the four
dengue virus serotypes has been shown to increase the risk of
DHF/DSS during infection with a second dengue virus sero-
type (5, 17, 45). Antibody-dependent enhancement of dengue
virus infection of monocytic cells has been proposed as one
explanation for this observation (18, 19, 37). We and others
have also proposed that serotype-cross-reactive dengue virus-
specific T cells play a role in the development of the plasma
leakage syndrome characteristic of DHF/DSS by releasing va-
soactive cytokines and lysing dengue virus-infected monocytes
(23, 29).
We have previously reported that DHF/DSS is characterized
by marked T-cell activation, as measured by serum levels of the
cytokines interleukin-2 (IL-2) and gamma interferon as well as
the soluble forms of CD4, CD8, and the a chain of the IL-2
receptor (25). Our laboratory has also identified some of the
molecular targets and in vitro functions of human dengue
virus-specific CD41 and CD81 T cells in bulk culture popula-
tions and at the clonal level (4, 14, 16, 22, 24, 26–28, 31, 32).
Murine T-cell responses have been a useful guide to under-
standing the human T-cell responses to human immunodefi-
ciency virus and hepatitis C virus (7, 21, 47, 48). We previously
described the serotype and protein specificity of murine den-
gue virus-specific CD41 and CD81 T cells in bulk culture
(42–44). We found both serotype-specific and serotype-cross-
reactive T-cell responses in the CD41 and CD81 populations,
similar to the observations for human dengue virus-specific T
cells. We also found murine CD81 T-cell responses to the
dengue virus nonstructural protein NS3, which has been a
target for human CD41 and CD81 cytotoxic T lymphocytes
(CTL).
In this study, we extend the previous observations on dengue
virus-specific murine T cells by isolating CD41 and CD81
T-cell clones, and we describe the serotype and protein spec-
ificity as well as the in vitro cytolytic functions of these T-cell
clones. For both CD41 and CD81 populations, some individ-
ual clones were serotype specific whereas others were serotype
cross-reactive. We identified T-cell clones specific for at least 4
of the 10 proteins of dengue virus type 2 (dengue-2 virus). All
of the CD81 T-cell clones and one of five CD41 T-cell clones
lysed dengue virus-infected cells in vitro. Two CD81 CTL
epitopes, one on the E protein (amino acids 331 to 339) and
one on the NS3 protein (amino acids 296 to 310), were mapped
by using synthetic peptides.
MATERIALS AND METHODS
Cells. Target cells were the A20 murine lymphoma line (H-2d), the P815
murine mastocytoma line (H-2d), the L929 murine fibroblast cell line (H-2k), and
L929 cells transfected with Ld (T1.1.1), Dd (T4.8.3; both from Carol Reiss, New
York University) (34), or Kd (L-Kd-172; from Jack Bennink, National Institutes
of Health) (10).
Mice.Male BALB/c (H-2d) mice were obtained from the Charles River Breed-
ing Laboratories (Wilmington, Mass.). Female B10.RDD (I-Ad1) mice were
generously provided by Chella David, Mayo Clinic (15). Mice were used between
4 and 12 weeks of age.
Viruses and viral antigens. Mouse-adapted dengue-1 virus (strain Hawaii),
dengue-2 virus (strain New Guinea C), dengue-3 virus (strain PR6), and den-
gue-4 virus (strain 814669) were generously provided as mouse brain homoge-
nates by Jack McCown, Walter Reed Army Institute of Research. Tissue culture-
adapted dengue-2 virus (strain New Guinea C) was kindly provided by Walter
Brandt, Walter Reed Army Institute of Research, and was propagated in C6/36
cells.
Recombinant vaccinia viruses expressing proteins of dengue-2 or dengue-4
virus under control of the vaccinia virus P7.5 early-late promoter were provided
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by C.-J. Lai, National Institute of Allergy and Infectious Diseases (2, 3, 11, 12, 42,
49). The dengue virus proteins expressed by these recombinant vaccinia viruses
are designated on the basis of the dengue virus serotype that served as the source
for cloning and the genome segment included. The range of proteins expressed
is listed on the basis of the order of proteins in the flavivirus polyprotein,
C–prM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5, where prM is the precursor
for the membrane protein M (pre-M).
Vero cell-derived dengue virus antigens were prepared as previously described
(26, 27, 44). Immunoaffinity-purified dengue-2 virus NS1 protein was provided by
Jacob Schlesinger, Rochester General Hospital (46). Purified dengue-2 virus E,
NS3, and NS5 proteins were provided by Margo Brinton, Georgia State Univer-
sity (23).
Synthetic peptides were prepared by 9-fluorenylmethoxycarbonyl chemistry
either in our laboratory by using the RaMPS multiple-peptide synthesizer (Du-
Pont) or in the Peptide Core facility at the University of Massachusetts Medical
Center by using a Symphony automated peptide synthesizer (Rainin Instru-
ments).
Generation of dengue virus-specific T-cell clones. Immunization of mice and
preparation of spleen cells were performed as previously described (42, 44).
Spleen cells (33 107) were incubated in 10 ml of RPMI 1640 supplemented with
2-mercaptoethanol (50 mM) and 10% fetal bovine serum (Hyclone Laboratories,
Inc., Logan, Utah) with 0.1 ml of Vero cell-derived dengue-2 virus antigen or 0.5
ml of dengue-2 virus (approximately 5 3 106 PFU). Proliferating cells were
restimulated every 1 to 2 weeks by culturing them in the presence of 10% rat
lectin-free T-cell growth factor (TCGF) as a source of IL-2 with either 3 3 107
g-irradiated syngeneic nonimmune spleen cells plus 1:100-diluted Vero cell-
derived dengue-2 virus antigen (for CD41 clones) or 2 3 106 g-irradiated,
dengue-2 virus-infected, major histocompatibility complex (MHC)-matched tar-
get cells (for CD81 clones).
Cloning of dengue virus-specific CD41 T cells was performed by limiting
dilution in 96-well flat-bottom plates with 106 g-irradiated syngeneic nonimmune
spleen cells per well in the presence of 1:100-diluted Vero cell-derived dengue-2
virus antigen and 10% rat TCGF.
Cloning of dengue virus-specific CD81 T cells was performed by limiting
dilution in 96-well U-bottom plates with 104 g-irradiated, dengue-2 virus-in-
fected, MHC-matched target cells per well in the presence of 10% rat TCGF.
Proliferation assays. Proliferation assays using CD41 T-cell clones were per-
formed at least 10 days after stimulation with antigen. T cells (2 3 104) were
incubated with g-irradiated syngeneic (except as noted) spleen cells (2 3 105)
and various concentrations of antigen in 0.2 ml of complete medium supple-
mented with 0.5% rat TCGF in each well of 96-well U-bottom plates. Plates were
incubated for 72 h at 378C. [3H]thymidine (1.25 mCi per well) was added for the
final 6 h of incubation. Cells were harvested onto glass filter paper with a
semiautomatic cell harvester (Skatron, Inc., Sterling, Va.), and the [3H]thymi-
dine incorporation was measured in a Betaplate liquid scintillation counter (LKB
Wallac Oy, Turku, Finland).
Cytotoxicity assays. Target cells were infected with dengue virus or vaccinia
viruses for 2 h and then incubated overnight at 378C. A20 target cells were
incubated overnight with Vero cell-derived antigens at a dilution of 1:20. Target
cells were labeled with 250 mCi of Na251CrO4 in 0.2 ml of medium for 1 h and
then seeded in 96-well U-bottom plates at 0.53 104 to 13 104 cells per well. For
experiments using synthetic peptides, peptides were added at various concentra-
tions directly to wells containing target cells.
CTL clones were added to plates at various effector/target ratios, and the
plates were incubated for 4 h at 378C. The supernatants were collected with a
Titertek harvester (Skatron), and 51Cr release was measured in a gamma
counter. Maximum 51Cr release was determined from wells containing target
cells and Renex (1:40); minimum 51Cr release was determined from wells con-
taining target cells and medium only. Percent specific lysis was calculated as
(experimental 51Cr release 2 minimum 51Cr release)/(maximum 51Cr release 2
minimum 51Cr release) 3 100.
Assays were performed in triplicate wells. The standard error of the mean of
samples did not exceed 10%. Minimum 51Cr release was generally less than 20%
of the maximum 51Cr release.
RESULTS
Serotype specificity of dengue virus-specific CD41 clones.
We stimulated dengue-2 virus-immune BALB/c splenocytes
with inactivated dengue virus antigens and isolated T-cell
clones by limiting dilution, as described for the isolation of
dengue virus-specific human CD41 T-cell clones (14, 16, 27,
28). Five T-cell clones were isolated. By fluorescent antibody
staining, all expressed the Thy11 CD41 CD82 phenotype.
Specificity of the clones for dengue virus was analyzed by
proliferation assay using inactivated dengue virus antigens (Ta-
ble 1). All of the clones showed proliferative responses to
dengue-2 virus antigen. Three of the five clones were dengue-2
virus specific, showing no proliferative response to antigens of
the other three serotypes. One clone showed a low but repro-
ducible proliferative response to dengue-4 virus antigen. The
fifth clone was broadly cross-reactive to all four dengue virus
serotypes and consistently showed the highest proliferative re-
sponse to dengue-4 virus antigen.
Protein specificity and MHC restriction of dengue virus-
specific CD41 clones. We next analyzed the proliferative re-
sponse of these T-cell clones to purified E, NS1, NS3, and NS5
proteins of dengue-2 virus. No proliferative responses by any of
the five clones were observed in assays using the E, NS3, and
NS5 proteins (data not shown). The dengue-2 virus-specific
clone 2A3 showed a concentration-dependent proliferation to
the purified dengue-2 virus NS1 protein (Table 2), whereas
none of the other four clones proliferated after incubation with
NS1 protein.
To determine the class II restriction of these CD41 clones,
we analyzed the proliferation of the clones in the presence
of irradiated spleen cells from BALB/c (I-Ad1 I-Ed1) and
B10.RDD (I-Ad1 I-Ed2) mice. The dengue-2 virus-specific
clone 2A1 proliferated in the presence of dengue-2 virus anti-
gen and spleen cells from both mouse strains (Table 3), indi-
cating that this clone recognizes dengue virus antigen in the
context of I-Ad, whereas the other four clones proliferated only
in the presence of BALB/c spleen cells, indicating that these
clones recognize dengue antigen in the context of I-Ed.
Cytotoxic activity of dengue virus-specific CD41 clones.We
tested these clones for cytotoxic activity by incubating them
with A20 target cells, which express H-2d class II antigens, in a
4-h chromium release assay. Only clone 2A2 lysed dengue-2
virus antigen-pulsed target cells (Table 4). In a separate ex-
periment, clone 2A2 also lysed dengue-2 virus-infected A20
cells but was unable to lyse dengue-2 virus-infected P815 cells,
TABLE 1. Proliferative responses of CD41 T-cell clones
to dengue virus antigens
Clone
Stimulation indexa to indicated antigen
D1 D2 D3 D4
2A1 0.4 2.5 0.6 0.5
2A2 0.5 136 0.4 4.3
2A3 1.3 6.4 1.4 1.3
2A4 5.3 11.5 19.7 50.5
2A5b 0.8 32 1.2 1.1
a Stimulation index 5 (cpm of cells incubated with indicated antigen)/(cpm of
cells incubated with control antigen). Data are listed as a composite of results
from four different experiments involving the five T-cell clones. Experimental
conditions were identical except as noted. D1 to D4 indicate antigens from
dengue-1 to dengue-4 viruses. Underlined values are significantly higher than
those for controls.
b Infectious virus (C6/36 culture supernatant) was used as the source of anti-
gen; culture supernatant from uninfected C6/36 cells was used as the control
antigen.
TABLE 2. Recognition of purified NS1 protein by
CD41 T-cell clone 2A3
Dilution
[3H]thymidine incorporation by
clone 2A3 (cpm)
Dengue-2 virus
NS1 protein Control
1:10 3,669 106
1:50 3,137 130
1:250 816 62
1:1,250 102 55
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which do not express class II MHC antigens (data not shown).
These data indicate that clone 2A2 is a cytotoxic CD41 clone.
Serotype and protein specificity of dengue virus-specific
CD81 clones. In vitro stimulation with inactivated antigens has
been shown to favor the growth of CD41 T cells (39). To select
for the growth of CD81 T cells, we stimulated dengue-2 virus-
immune BALB/c splenocytes with infectious dengue-2 virus
and then maintained the cells by stimulation with g-irradiated,
dengue-2 virus-infected P815 cells in the presence of IL-2.
Cells were then cloned by limiting dilution. Clones were
screened for specific cytotoxic activity against dengue-2 virus-
infected P815 cells. Representative results are shown in Table
5. None of the clones isolated lysed uninfected P815 cells
(Table 5 and data not shown). All of the clones tested ex-
pressed the Thy11 CD42 CD81 phenotype. The serotype and
protein specificity of the clones was determined by testing for
lysis of P815 target cells infected with recombinant vaccinia
viruses expressing dengue virus proteins.
We identified at least six different types of dengue virus-
specific CTL clones. Three of these CTL clones recognized
target cells infected with vvD2:C-prM-E, which expresses the
dengue-2 virus structural proteins, as exemplified in Table 5 by
clones 2D13, 2E-56, and 2E-60. Clone 2D13 recognized target
cells infected with vvD2:E, which expresses only the dengue-2
virus E protein (Table 5, experiment 1), as did clone 2E-60
(Table 5, experiment 5), although the specific epitopes recog-
nized differed (see below). Clone 2E-56 recognized target cells
infected with vvD2:prM, which expresses only the pre-M pro-
tein (Table 5, experiment 5). None of these clones recognized
the dengue-4 virus structural proteins expressed by recombi-
nant vaccinia virus vvD4:C-prM-E-NS1-NS2A (data not shown),
suggesting that these CTL clones were serotype specific.
Two different CTL recognized dengue virus nonstructural
proteins, as exemplified in Table 5 by clones 2D42, 2D65, and
2E-67. Clone 2D42 recognized target cells infected with vvD2:
NS3, which expresses the dengue-2 virus NS3 protein (Table 5,
experiment 1), or vvD4:NS3 (Table 5, experiment 2), which
expresses the dengue-4 virus NS3 protein. Clone 2D65 also
recognized the dengue-2 and dengue-4 virus NS3 protein (Ta-
ble 5, experiment 2). Clone 2E-67 recognized target cells in-
fected with vvD2:NS1-NS2A-NS2B, which expresses the den-
gue-2 virus NS1 and NS2A proteins and most of the NS2B
protein, as well as target cells infected with vvD4:NS1-NS2A,
which expresses the dengue-4 virus NS1 and NS2A proteins
(Table 5, experiment 4). These results indicate that these CTL
clones specific for nonstructural proteins were serotype cross-
reactive.
Some CTL clones recognized none of the available recom-
binant vaccinia viruses, although they did recognize dengue-2
virus-infected target cells, as exemplified by clones 2D7 (Table
5, experiment 3) and 2E-8 (Table 5, experiment 4). Thus, there
must be at least a sixth CTL specificity. From analyses using
the available recombinant vaccinia viruses, this epitope may lie
on the N terminus of C, on the C terminus of NS2B, or on the
NS4A, NS4B, or NS5 protein.
MHC restriction of recognition by CD81 CTL clones. We
studied the MHC restriction of recognition of some of the CTL
clones, using target cells sharing only one of the H-2d class I
genes. In these experiments, we used clone 2D13, which rec-
ognized the dengue-2 virus E protein (Table 5), and clones
2D42, 2D63, and 2D65, which all recognized the dengue-2
virus NS3 protein (Table 5 and data not shown). Clone 2D13
recognized dengue-2 virus-infected target cells which ex-
pressed the Ld antigen, whereas clones 2D42, 2D63, and 2D65
recognized dengue-2 virus-infected target cells which ex-
pressed the Kd antigen (Table 6).
Mapping of CTL epitopes on E and NS3 proteins. We used
synthetic peptides to identify the specific epitopes recognized
on the E and NS3 proteins. To map the epitope on the NS3
protein, we first tested for recognition of recombinant vaccinia
viruses expressing portions of the dengue-4 virus NS3 protein;
this analysis indicated that the epitope was located in the
middle one-third of the NS3 protein (data not shown). We
then prepared 22 overlapping 15-residue synthetic peptides
covering the region of interest excluding peptides that were not
highly conserved between dengue-2 and dengue-4 viruses. We
then tested these peptides for the ability to sensitize uninfected
P815 target cells for recognition by the Kd-restricted, NS3-
specific CTL clones 2D42 and 2D65. Both CTL clones recog-
nized target cells incubated with the overlapping peptides 10
and 11 (Table 7). Peptide 10, which was recognized to a greater
extent, represents amino acids 296 to 310 of the NS3 protein,
ARGYISTRVEMGEAA, which is completely conserved in
dengue-2 and dengue-4 viruses. Four other CTL clones, in-
cluding clone 2D63, also recognized this epitope (data not
shown).
To map the epitope on the E protein recognized by clone
2D13, we identified all 9-mer peptides containing a proline at
position 2, which is an anchor residue for binding to the Ld
antigen (13). Of 19 peptides which met this requirement, we
selected 7 peptides for synthesis after preliminary studies
which showed an absence of recognition of a panel of E pep-
tides obtained from John Roehrig, Centers for Disease Con-
trol and Prevention, Fort Collins, Colo. (data not shown).
When these seven peptides were tested for the ability to sen-
sitize target cells for lysis by clone 2D13, only one peptide,
E(331-339), representing amino acids 331 to 339 of the E
protein (SPCKIPFEI), was recognized (Table 8). At least 20
other CTL clones which also recognized this E(331-339)
epitope were isolated. However, clone 2E-60, which recog-
nized the dengue-2 virus E protein, did not recognize peptide
E(331-339) or any of the peptides listed in Table 8 (data not
TABLE 3. MHC restriction of proliferative responses of
dengue virus-specific CD41 T-cell clones
Clone
Stimulation indexa obtained with stimulator cells from
indicated mouse strain (H-2d class II allele[s])
BALB/c (I-Ad, I-Ed) B10.RDD (I-Ad)
2A1 16 9.3
2A2 4.3 1.4
2A3 61 1.3
2A4 25 1.3
2A5 6.2 1.1
a Stimulation index 5 (cpm of cells incubated with dengue-2 virus antigen)/
(cpm of cells incubated with control antigen). Underlined values are significantly
higher than those for controls.
TABLE 4. Cytolytic activity of CD41 clone 2A2
Effector/target
ratio
% Specific lysis of A20 target cells pulsed witha:
Antigen from: No
antigenD1 D2 D3 D4 Control
10:1 0 57 0 2 ,0 1
5:1 1 46 0 1 0 0
a A20 target cells were incubated overnight with the indicated antigen; anti-
gens were prepared as sonic extracts of Vero cells infected with dengue-1 virus
(D1), dengue-2 virus (D2), dengue-3 virus (D3), dengue-4 virus (D4), or no virus
(control). Underlined values are significantly higher than those for controls.
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shown), indicating that there is a second epitope on the E
protein recognized by H-2d CTL. Six other CTL clones recog-
nized the dengue-2 virus structural proteins but have not been
further characterized.
DISCUSSION
We isolated dengue virus-specific CD41 and CD81 T-cell
clones from dengue-2 virus-immunized BALB/c (H-2d) mice.
Our findings show a surprising level of heterogeneity in the
protein specificity, serotype specificity, and MHC restriction of
dengue virus-specific CD41 and CD81 T cells in this mouse
strain. We identified at least five distinct in vitro phenotypes of
CD41 clones and six distinct phenotypes of CD81 clones, as
summarized in Table 9.
Among the CD41 T-cell clones isolated after primary den-
gue virus infection, serotype-specific proliferative responses
were more common than serotype-cross-reactive responses.
However, one of five CD41 clones was broadly serotype cross-
reactive, with the highest proliferative response to dengue-4
virus antigens, although the clone was derived from a dengue-2
virus-immunized animal. This pattern of T-cell response has
not yet been noted in our studies of dengue virus-immune
humans and supports the notion that primary dengue virus
infection can induce the proliferation of a wide variety of
dengue virus serotype-cross-reactive T-cell clones. Among
CD81 T-cell clones, those clones which recognized structural
proteins were serotype specific and those which recognized
nonstructural proteins were serotype cross-reactive, consistent
with the observation that the nonstructural proteins, particu-
larly NS1, NS3, and NS5, are more highly conserved among the
four dengue virus serotypes (40).
One CD41 T-cell epitope was localized to the NS1 protein.
CD81 T-cell epitopes were localized to the pre-M, E (two
separate epitopes), NS1/NS2A, and NS3 proteins. A sixth
epitope could not be definitively mapped with the available
recombinant vaccinia viruses. One of the epitopes on the E
protein was mapped to residues 331 to 339 and was shown to
be restricted by the H-2Ld antigen. The epitope on the NS3
protein was mapped to residues 296 to 310 and was shown to
be restricted by the H-2Kd antigen.
The CD81 T-cell clones were identified on the basis of their
ability to lyse dengue virus-infected target cells. We also found
that one of the five CD41 clones isolated demonstrated MHC
class II-restricted killing of dengue virus-infected or antigen-
pulsed cells. In contrast, almost all human dengue virus-spe-
cific CD41 clones that we have studied have expressed cytolytic
function in vitro (14, 16, 22, 27, 32). Our results with murine
CD41 T-cell clones are similar to the findings of other inves-
tigators (9, 33); the higher frequency of cytolytic function
among dengue virus-specific human CD41 T cells may reflect
the importance of HLA class II antigen-positive cells in dengue
virus replication in vivo (18, 19, 23, 29).
Our data on the specificity of dengue virus-specific T-cell
clones correlated well, in general, with the results obtained in
the analysis of BALB/c dengue virus-specific T cells at the bulk
culture level (42, 44). Proliferative responses of CD41 T cells
in bulk cultures were predominantly serotype specific, with a
low level of serotype cross-reactivity. Our previous bulk culture
analyses had shown that dengue virus-specific BALB/c CD41
T cells recognized the NS1 protein (43) and CD81 T cells
recognized the NS3 and NS1/NS2A proteins as well as one (or
more) of the structural proteins (42). However, the data from
the analyses of dengue virus-specific T cells in bulk culture and
at the clonal level disagreed on two points. First, spleen cells
from dengue-4 virus-immunized BALB/c mice showed a spe-
cific proliferative response to recombinant baculovirus-ex-
pressed dengue-4 virus E protein (43), whereas none of the
dengue-2 virus-induced CD41 T-cell clones proliferated in re-
TABLE 5. Recognition of dengue virus proteins by dengue virus-specific CTL clones
Effector
Effector/
target
ratio
% Specific lysis of P815 target cells infected witha:
Dengue-2
virus
No
virus
Vaccinia
virus
control
vvD2:C-prM-E vvD2:prM vvD2:E vvD2:NS1-NS2A-NS2B vvD2:NS3
vvD4:NS1-
NS2A vvD4:NS3
Expt 1
2D13 2:1 35 0 0 36 NT 25 2 ,0 NT NT
2D42 2:1 35 5 1 1 NT NT 2 39 NT NT
Expt 2
2D42 2:1 62 8 1 NT NT NT NT 49 NT 48
2D65 2:1 64 3 2 NT NT NT NT 53 NT 51
Expt 3
2D7 6:1 39 4 3 4 NT NT 1 9 NT NT
Expt 4
2E-8 5:1 26 ,0 0 0 NT NT ,0 ,0 0 NT
2E-60 5:1 38 0 ,0 22 NT NT 3 ,0 ,0 NT
2E-67 5:1 34 5 3 5 NT NT 14 2 18 NT
Expt 5
2E-56 5:1 NT NT ,0 41 30 ,0 NT NT NT NT
2E-60 5:1 NT NT ,0 20 ,0 28 NT NT NT NT
a Underlined values are significantly higher than those for controls. NT, not tested.
TABLE 6. MHC restriction of CTL activity of dengue
virus-specific CD81 T-cell clones
Target cell H-2
d
antigen(s) Virus
% Specific lysis by indicated clonea
Expt 1 Expt 2
2D13 2D63 2D42 2D65
P815 K, L, D None ,0 ,0 1 ,0
D2Vb 44 22 84 80
T4.8.3 D D2V 1 4 NT NT
T1.1.1 L D2V 22 1 NT NT
L-Kd-172 K D2V 1 18 55 31
DAP D2V 2 2 3 2
a Underlined values are significantly higher than those for controls. NT, not
tested.
b D2V, dengue-2 virus.
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sponse to purified dengue-2 virus E protein. Second, CTL
generated in bulk culture from dengue-4 virus-immunized
BALB/c mice did not recognize the dengue-4 virus E protein
(42), whereas many of the CD81 clones that we isolated from
dengue-2 virus-immunized mice recognized the dengue-2 virus
E protein. Since we studied a small number of CD41 clones,
we cannot exclude sampling as the explanation for the first
observation, and indeed other investigators have shown that
the dengue-2 virus E protein contains helper T-cell epitopes
(30, 41). However, an alternative explanation for both findings
is that immunization with different dengue virus serotypes may
generate different patterns of CD41 and CD81 responses.
Amino acid differences between the different dengue virus
serotypes might involve critical anchor residues affecting bind-
ing to specific MHC molecules. This could have important
implications for the development of synthetic vaccines against
dengue virus infection, because comparable responses to each
of the four dengue virus serotypes cannot be assumed.
Protective immunity against lethal encephalitis has been
elicited in BALB/c mice by immunization with recombinant
vaccinia viruses expressing dengue virus pre-M, E, or NS1
protein (2, 8, 11, 35, 46). The mechanism of protective immu-
nity has not been clearly defined. Although in some cases
protection could be passively transferred with serum, protec-
tion has not correlated with the generation of antibodies ca-
pable of neutralizing dengue virus in vitro (2, 11, 35, 46). Our
results suggest that the generation of dengue virus-specific
CTL responses could provide one mechanism of protection in
these studies.
The human CD41 T-cell response to dengue virus has been
studied in greater detail than the CD81 T-cell response to this
virus. Nonetheless, the findings presented here indicate that
murine and human T-cell responses to dengue virus are qual-
itatively similar with regard to recognition of heterologous
dengue virus serotypes and cytolytic function. Some human
subjects had a higher frequency of serotype-cross-reactive T-
cell clones than others (16, 27), which could be influenced by
the serotype of dengue virus with which they have been in-
fected and their HLA antigens. Most human dengue virus-
specific CD41 T-cell clones have shown the Th1 phenotype,
producing gamma interferon and IL-2 and lysing dengue virus-
infected MHC class II-expressing cells (14a, 27). We found
that one of five murine dengue virus-specific CD41 T-cell
clones had cytolytic function in vitro; however, we have not
detected IL-2 (or IL-4) production by these clones in vitro in a
bioassay in CTLL cells (data not shown). We have hypothe-
sized that the pattern of cytokine production, the cytolytic
function, and the proportion of serotype-cross-reactive cells all
might influence the immune response to infection with a sec-
ond dengue virus serotype and could affect the likelihood of an
immunopathological response leading to DHF/DSS.
Some investigators have reported that murine and human T
cells recognize identical or overlapping epitopes in human
immunodeficiency virus and hepatitis C virus (7, 21, 47, 48).
Although we have found that some human and murine dengue
virus-specific T cells recognize the same proteins, such as the
E, NS1/NS2A, and NS3 proteins, we have not yet found an
example of overlapping epitopes. Our approach differed from
that of these other groups in that we have not used the pep-
tides recognized by murine T cells to test for a corresponding
response in humans. In addition, our results suggest that the
specificity of the T-cell response may be influenced by the
serotype of dengue virus eliciting the response, and we have
studied a limited number of subjects, both human and murine,
to date. Further studies will be necessary to determine if mu-
rine and human T cells can recognize the same dengue virus
epitope(s).
These results indicate that the murine T-cell response to
dengue virus includes the features that are hypothesized to
relate to a T-cell-mediated immunopathological response to
secondary dengue virus infection. Although some investigators
have observed increased capillary permeability during dengue
virus infection of mice (6), most investigators have failed to
develop a murine model for DHF/DSS. This might relate to
the failure of dengue virus to replicate to detectable levels in
blood or tissues in mice (1), which would reduce the stimulus
for the T-cell response, or to a reduced sensitivity of mice to
the effects of T-cell activation and cytokine production, as has
TABLE 7. Recognition of NS3 peptides by CD81 CTL clones
Peptide
(0.1 mM)
% Specific lysis by clonea:
2D42 2D65
None ,0 ,0
1-9 ,0 ,0
10 77 48
11 40 12
12-22 ,0 ,0
a Underlined values are significantly higher than those for controls.
TABLE 8. Recognition of E peptides by CD81 CTL clone 2D13
P815 target cell
(peptide [2.5 mM]) Sequence
% Specific
lysisa
Dengue-2 virus infected 20
No peptide (uninfected) 0
E(131-139) QPENLEYTI 0
E(165-173) TPQSSITEA 0
E(216-224) LPLPWLPGA 0
E(218-226) LPWLPGADT 1
E(221-229) LPGADTQGS 2
E(331-339) SPCKIPFEI 56
E(383-391) EPGQLKLNW 4
a Underlined values are significantly higher than those for controls.
TABLE 9. Summary of functional phenotypes of dengue
virus-specific T-cell clones studied
Example(s) Cytolyticactivity
MHC
restric-
tion
Serotype
specificity
Protein
recognized
Epitope
recognized
CD41 clones
2A1 No I-Ad D2 —a —
2A2 Yes I-Ed D2 .. D4 — —
2A3 No I-Ed D2 NS1 —
2A4 No I-Ed D4 . D3 .
D2 . D1
— —
2A5 No I-Ed D2 — —
CD81 clones
2E-56 Yes — D2 Pre-M —
2D13 Yes Ld D2 E 331-339
2E-60 Yes — D2 E —
2E-67 Yes — D2, D4 NS1/NS2A —
2D42, 2D63,
2D65
Yes Kd D2, D4 NS3 296-310
2D7, 2E-8 Yes — D2b — —
a—, not determined.
b Recognition of other dengue virus serotypes was not definitively determined
because the appropriate recombinant vaccinia viruses were not available.
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been observed for endotoxin in some mouse strains (38). We
are studying the possibility that these dengue virus-specific
T-cell clones might permit a further analysis of this phenom-
enon.
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